54
ANZUP ANNUAL REPORT 2021
RESEARCH HIGHLIGHTS
Publications and Presentations 2020/21 Presentations TheraP ASCO, 29 May - 2 June 2020 Oral presentation by Michael Hofman. TheraP: A randomised phase 2 trial of Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel - initial results (ANZUP protocol 1603).
BL.12 JAMA Oncology, 17 September 2020 Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer Srikala S. Sridhar, MD; Normand Blais, MD; Ben Tran, MD; M. Neil Reaume, MD; Scott A. North, MD; Martin R. Stockler, MD; Kim N. Chi, MD; Neil E. Fleshner, MD; Geoffrey Liu, MD; John W. Robinson, MD; Som D. Mukherjee, MD; Yasmin Rahim, MD; Eric Winquist, MD; Christopher M. Booth, MD; Nghia Trung Nguyen, MD; Emma K. Beardsley, MD; Nimira S. Alimohamed, MD; Gail T. McDonald, MSc; Keyue Ding, PhD; Wendy R. Parulekar, MD RAVES The Lancet, 28 September 2020 Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial Andrew Kneebone, Carol Fraser-Browne, Gillian M Duchesne, Richard Fisher, Mark Frydenberg, Alan Herschtal, Scott G Williams, Chris Brown, Warick Delprado, Annette Haworth, David J Joseph, Jarad M Martin, John H L Matthews, Jeremy L Millar, Mark Sidhom, Nigel Spry, Colin I Tang, Sandra Turner, Kirsty L Wiltshire, Henry H Woo, Ian D Davis, Tee S Lim, Maria Pearse.
Publications e-TC 2.0 Journal of Psychosocial Oncology Research and Practice, 31 August 2020 Online psychological self-management intervention for testicular cancer survivors: promising acceptability and preliminary efficacy, but limited feasibility Allan ‘Ben’ Smith, Orlando Rincones, Louise Heiniger, Peter Grimison, Ben Tran, Martin R. Stockler, Guy Toner, Beth Cohen, Ian Olver, Britt Klein, Margaret McJannett, Phyllis Butow
SORCE ASCO Journal of Clinical Oncology, 14 October 2020 Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial Tim Eisen, MB BChir, PhD; Eleni Frangou, MSc (Res); Bhavna Oza, MBBS2; Alastair W.S. Ritchie, MD; Benjamin Smith, BSc; Rick Kaplan, MD; Ian D. Davis, MBBS, PhD; Martin R. Stockler, MBBS, MSc; Laurence Albiges, MD, PhD; Bernard Escudier, MD; James Larkin, PhD; Axel Bex, MD, PhD; Steven Joniau, MD, PhD; Barry Hancock, MD; Gregers G. Hermann, MD, DMSc; Joaquim Bellmunt, MD, PhD; Elizabeth Hodgkinson, BPharm, MSc; Grant D. Stewart, MBChB; Jim Barber, DM; Janet Brown, MD; Rhona McMenemin, MSc; Paul Nathan, MBBS, MD; Lisa M. Pickering, PhD;Mahesh K.B. Parmar, DPhil; and Angela Meade, DPhil.
